Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving cancer treatment.
Skip Nav Destination
Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism
December 30, 2021
Content License:Private